Literature DB >> 8105796

Seizure promotion by D1 agonists does not correlate with other dopaminergic properties.

M S Starr1, B S Starr.   

Abstract

A range of D1 receptor agonists were tested for their ability to facilitate limbic motor seizures induced by a subthreshold dose of the chemoconvulsant pilocarpine (100 mg/kg IP) in mice. ED50 values (mumol/kg) were calculated from log dose-probit analyses, giving relative proconvulsant potencies of SKF 82958 > CY 208-243 > SKF 77434 = SKF 75670 = SKF 80723 > SKF 38393. The compound SKF 82526, which poorly crosses the blood-brain barrier, did not lower the seizure threshold. Convulsions consisted of rearing and forepaw myoclonus, leading to status epilepticus at higher doses of the D1 agonists. No deaths were recorded. A maximum seizure incidence of 50% was obtained with SKF 75670, compared to 100% for the other compounds. Apart from SKF 82526, the D1 agonists all elicited behavioural signs of central D1 receptor stimulation, including motor restlessness, grooming and sniffing. There was no obvious relationship between the abilities of these D1 agonist drugs to promote epilepsy and their effects on unconditioned motor behaviour, or their affinities and efficacies at the striatal D1 receptor. It is concluded that a reduction of the seizure threshold is an inevitable consequence of central D1 receptor stimulation with existing D1 agonists.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105796     DOI: 10.1007/bf02252620

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  10 in total

1.  Dopamine depresses excitatory and inhibitory synaptic transmission by distinct mechanisms in the nucleus accumbens.

Authors:  S M Nicola; R C Malenka
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  Dopamine D1 vs D5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling.

Authors:  Gerard J O'Sullivan; Mark Dunleavy; Kerstin Hakansson; Mario Clementi; Anthony Kinsella; David T Croke; John Drago; Allen A Fienberg; Paul Greengard; David R Sibley; Gilberto Fisone; David C Henshall; John L Waddington
Journal:  Neuropharmacology       Date:  2008-02-21       Impact factor: 5.250

Review 3.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

4.  Convulsant doses of a dopamine D1 receptor agonist result in Erk-dependent increases in Zif268 and Arc/Arg3.1 expression in mouse dentate gyrus.

Authors:  Giuseppe Gangarossa; Manuela Di Benedetto; Gerard J O'Sullivan; Mark Dunleavy; Cristina Alcacer; Alessandra Bonito-Oliva; David C Henshall; John L Waddington; Emmanuel Valjent; Gilberto Fisone
Journal:  PLoS One       Date:  2011-05-03       Impact factor: 3.240

5.  Cell signaling underlying epileptic behavior.

Authors:  Yuri Bozzi; Mark Dunleavy; David C Henshall
Journal:  Front Behav Neurosci       Date:  2011-08-02       Impact factor: 3.558

6.  Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy.

Authors:  Su-Hyuk Chi; Hyun-Ghang Jeong; Suji Lee; So-Young Oh; Seung-Hyun Kim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

7.  Obligatory roles of dopamine D1 receptors in the dentate gyrus in antidepressant actions of a selective serotonin reuptake inhibitor, fluoxetine.

Authors:  Takahide Shuto; Mahomi Kuroiwa; Naoki Sotogaku; Yukie Kawahara; Yong-Seok Oh; Jin-Hyeok Jang; Chang-Hoon Shin; Yoshinori N Ohnishi; Yuuki Hanada; Tsuyoshi Miyakawa; Yong Kim; Paul Greengard; Akinori Nishi
Journal:  Mol Psychiatry       Date:  2018-12-10       Impact factor: 15.992

8.  Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor.

Authors:  Tim J Fyfe; Peter J Scammells; J Robert Lane; Ben Capuano
Journal:  Molecules       Date:  2021-06-22       Impact factor: 4.411

9.  The role of dopamine signaling in epileptogenesis.

Authors:  Yuri Bozzi; Emiliana Borrelli
Journal:  Front Cell Neurosci       Date:  2013-09-17       Impact factor: 5.505

10.  Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.

Authors:  Amit Desai; Lauren Benner; Ruishan Wu; Lev Gertsik; Tolga Uz; Gerard J Marek; Tong Zhu
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.